Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001654921 | SCV001869356 | benign | not provided | 2021-03-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001654921 | SCV002406933 | benign | not provided | 2025-01-13 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003458742 | SCV004179706 | benign | Developmental and epileptic encephalopathy, 69 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004968228 | SCV005552700 | likely benign | Inborn genetic diseases | 2024-10-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003948654 | SCV004764094 | likely benign | CACNA1E-related disorder | 2019-11-01 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |